Table 2.
MT | cMF 60% | |||||||
---|---|---|---|---|---|---|---|---|
MC% | SRM | P | RMSCV% | MC% | SRM | P | RMSCV% | |
VC | −2.3 | −0.44 | .03 | 2.5% | −3.5 | −0.32 | .10 | 2.6% |
tAB | 0.5 | 0.37 | .06 | 1.0% | −0.1 | −0.04 | .84 | 1.1% |
AC | −0.9 | −0.33 | .09 | 1.0% | −1.7 | −0.22 | .26 | 1.3% |
cAB | −1.0 | −0.29 | .14 | 1.0% | −3.0 | −0.36 | .07 | 1.1% |
VCtAB | −2.7 | −0.59 | .00 | 1.9% | −4.0 | −0.33 | .09 | 2.0% |
ThCtAB.aMe | −2.6 | −0.58 | .01 | 1.9% | −3.6 | −0.31 | .12 | 1.7% |
ThCtAB.bMe | −2.8 | −0.62 | .00 | 1.9% | −3.3 | −0.29 | .13 | 1.9% |
ThCtAB.cMe | −2.5 | −0.56 | .01 | 2.0% | −3.9 | −0.33 | .10 | 1.7% |
ThCcAB.aMe | −1.4 | −0.43 | .03 | 1.9% | −1.5 | −0.18 | .34 | 1.7% |
ThCcAB.bMe | −1.5 | −0.48 | .02 | 1.9% | −1.2 | −0.15 | .43 | 1.9% |
ThCcAB.cMe | −1.3 | −0.42 | .04 | 2.0% | −2.0 | −0.23 | .23 | 1.7% |
ThCtAB.aMax | −1.4 | −0.27 | .17 | 4.4% | 0.0 | 0.00 | .99 | 2.8% |
ThCtAB.bMax | −1.7 | −0.30 | .12 | 4.2% | 0.7 | 0.10 | .61 | 3.3% |
ThCtAB.cMax | −1.1 | −0.18 | .35 | 5.3% | −0.5 | −0.09 | .65 | 3.2% |
ThCtAB.aMav | −1.4 | −0.31 | .11 | 3.8% | −0.3 | −0.05 | .79 | 2.5% |
ThCtAB.bMav | −1.7 | −0.35 | .07 | 3.5% | 0.0 | 0.00 | .98 | 2.8% |
ThCtAB.cMav | −1.3 | −0.25 | .19 | 4.5% | −0.5 | −0.09 | .65 | 2.8% |
MC%: mean change in %, SRM: standardized response mean (= mean change/SD of change), P: level of significance of change using a paired t-test without adjustment for multiple comparisons; RMSCV%: root mean square coefficient of variation of test-retest acquisitions at baseline, with repositioning in between scans. For other abbreviations, please see Table 1. Note that values are given for the “long” femoral region of interest, that is, a 60% distance between the trochlear notch and the posterior end of both femoral condyles.